MMAE-d₈ (Synonyms: Monomethyl auristatin E-d₈; Deuterated labeled MMAE)

Name: MMAE-d 8
Brand: MedChemExpress
SKU: HY-15162A
Rating: 5.0 (8 reviews)

Cat. No.: HY-15162A Purity: 99.15%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

MMAE-d₈ is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.

For research use only. We do not sell to patients.

MMAE-d₈ Chemical Structure

CAS No. : 2070009-72-0

Size	Price	Stock	Quantity
1 mg	USD 1320	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 3000	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 4500	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of MMAE-d₈:

Monomethyl auristatin E In-stock

8 Publications Citing Use of MCE MMAE-d₈

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

MMAE-d₈ is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.

IC₅₀ & Target

Auristatin

In Vitro

Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs are generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. LC-MS is used to measure the concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume is not different among treatment groups 3 days after dose, the intratumoral MMAE measurement reveals two patterns. First, intratumoral MMAE concentration increases proportionally to the ADC dose, which correspondes to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from treatment with both cOKT9-vcMMAE and cAC10-vcMMAE is similar at each dose, consistent with the observation that tumor responded similarly to these two ADCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Intratumoral MMAE concentrations consistently correlates with the extent of tumor growth inhibition in tumor xenograft models. IHC analysis reveals that nonbinding control-treated tumors consist of both CD30⁺ and CD30^-cells, presumably because they do not kill either CD30⁺ or CD30^- Karpas 299 cells. Only CD30^- cells are found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminates most CD30⁺ cells. Interestingly, the two tumors that relapses from cAC10-vcMMAE treatment are also found to be CD30^- by the end of study, indicating a small fraction of CD30^- cells might have escaped from bystander killing in these two remaining tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

726.03

Formula

C₃₉H₅₉D₈N₅O₇

CAS No.

2070009-72-0

Unlabeled CAS

474645-27-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1[C@H]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)CCC1)=O)C)[C@@]([2H])(NC([C@@H](NC)C(C)C)=O)C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (137.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.3774 mL	6.8868 mL	13.7735 mL
5 mM	0.2755 mL	1.3774 mL	2.7547 mL
10 mM	0.1377 mL	0.6887 mL	1.3774 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.29%

Select Batch:

Data Sheet (279 KB) SDS (252 KB)

COA (254 KB) RP-HPLC (117 KB)

Handling Instructions (2659 KB)

References

[1]. Li F, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016 May 1;76(9):2710-9. [Content Brief]

Kinase Assay
^[1]

Cell pellets are collected 24 hours after ADC treatment. Cell count, diameter, and circularity are determined on Vi-Cell Counter. MMAE extraction and quantification method is performed. Briefly, tumors or cell pellets are homogenized with methanol and acetonitrile containing internal standard (d⁸-MMAE for MMAE detection and ¹³C-MMAF for MMAF detection). The homogenates are centrifuged at 10,000 rpm to precipitate protein and protein-bound payloads. The supernatant is then subjected to solid phase extraction, and signals of MMAE and MMAF are detected by LC-MS^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Li F, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016 May 1;76(9):2710-9. [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.3774 mL	6.8868 mL	13.7735 mL	34.4338 mL
	5 mM	0.2755 mL	1.3774 mL	2.7547 mL	6.8868 mL
	10 mM	0.1377 mL	0.6887 mL	1.3774 mL	3.4434 mL
	15 mM	0.0918 mL	0.4591 mL	0.9182 mL	2.2956 mL
	20 mM	0.0689 mL	0.3443 mL	0.6887 mL	1.7217 mL
	25 mM	0.0551 mL	0.2755 mL	0.5509 mL	1.3774 mL
	30 mM	0.0459 mL	0.2296 mL	0.4591 mL	1.1478 mL
	40 mM	0.0344 mL	0.1722 mL	0.3443 mL	0.8608 mL
	50 mM	0.0275 mL	0.1377 mL	0.2755 mL	0.6887 mL
	60 mM	0.0230 mL	0.1148 mL	0.2296 mL	0.5739 mL
	80 mM	0.0172 mL	0.0861 mL	0.1722 mL	0.4304 mL
	100 mM	0.0138 mL	0.0689 mL	0.1377 mL	0.3443 mL

MMAE-d₈ Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MMAE-d₈2070009-72-0Monomethyl auristatin E-d₈Deuterated labeled MMAEMicrotubule/TubulinADC CytotoxinADC PayloadInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

MMAE-d8 (Synonyms: Monomethyl auristatin E-d8; Deuterated labeled MMAE)

Customer Review

Other Forms of MMAE-d8:

MMAE-d8 Related Antibodies

8 Publications Citing Use of MCE MMAE-d8

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

MMAE-d8 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MMAE-d8 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report

MMAE-d₈ (Synonyms: Monomethyl auristatin E-d₈; Deuterated labeled MMAE)

Other Forms of MMAE-d₈:

MMAE-d₈ Related Antibodies

8 Publications Citing Use of MCE MMAE-d₈

MMAE-d₈ Related Antibodies

MMAE-d₈ Related Classifications